ScreenPoint Medical

Our Co-founder and CSO, Prof. Nico Karssemeijer, and Co-founder of Biomediq, Prof. Mads Nielsen, spoke to Brian Casey about about how AI is moving beyond image analysis to enable risk prediction for breast cancer. On The Imaging Wire show, they discussed how AI-driven breast screening is changing. By combining #Transpara with advanced risk assessment from Biomediq, we are here to empower radiologists to see more than ever before. 👉 Watch the full conversation here: https://lnkd.in/gsJqgCdY 

👋 ScreenPoint Medical at #ECR 2025! 👋 We’re excited to be part of ECR 2025 in Vienna from Feb 26 – Mar 2! This year’s theme, PLANET RADIOLOGY, highlights the impact of radiology on healthcare and beyond. 📍 We'll be at ACV Level -2, EXPO X1, Booth AI-12! Book a 15 minute demo with us to see #Transpara in action! https://lnkd.in/ejQ3BpBs See you there! #Radiology #HealthAI

🔥 MASAI NEW PUBLICATION WITH TRANSPARA-POWERED RESULTS! 🔥 On World Cancer Day, we highlight the power of early detection. The MASAI trial confirms that screening with #Transpara delivers unprecedented results, advancing the fight against breast cancer. ✅ 29% increase in Cancer Detection Rate (CDR) ✅ 44% reduction in screening workload ✅ No increase in recalls, false positives, or consensus meetings And? Clinically meaningful early detection in catching more small, lymph node negative invasive cancers that impact treatment and prognosis. "Downstaging by earlier detection with use of AI is possible, which could be of clinical benefit since stage has a major influence on breast cancer treatment and prognosis" MASAI remains the first and only true Randomized Controlled Trial (RCT) for #AI in breast cancer screening, conducted under the most rigorous testing conditions. Compared to alternatives, MASAI’s approach showed a larger increase in cancer detection, highlighting the impact of AI software choice and integration method. Final results will include interval cancer outcomes – stay tuned for updates! 👋 Curious to learn more? Let's talk at ECR! See you there! 👋 Lång et al., 2025, Lancet Digital Health #HealthAI #BreastAI

At #ECR 2024, we connected with brilliant minds, explored innovations, and showcased how Transpara delivers WORKFLOW, CONFIDENCE, RESULTS ✨ A big THANK YOU to everyone who visited our booth, sparked conversations, and shared invaluable feedback. Now, we’re gearing up for ECR 2025 in Vienna! Ready to embrace the theme PLANET RADIOLOGY and discover how we can support a more sustainable future for breast imaging, as we collectively shape the next frontier in #radiology. Until then, here’s a look back at some of our favorite moments from last year! 🌟 #HealthAI #BreastAI

Dense breast tissue affects more than 30% of women, increasing their risk of breast cancer and making early detection more difficult. However, combining AI with radiologists’ expertise has been shown to improve detection rates by an average of no less than 20%, offering a vital solution for these women. Our CEO Pieter Kroese and co-founder Dr. Nico Karssemeijer, recently shared their perspective in the Netherlands, where ScreenPoint Medical was founded, on the urgent need for #AI in breast cancer detection. Read more about our perspective here: https://lnkd.in/eBsHbqzE Zorgvisie #HealthAI #BreastAI

We're thrilled to announce the acquisition of Biomediq A/S, a partnership built on a decade of collaboration. This milestone strengthens our commitment to innovative approaches in early breast cancer detection. The 2023 Lauritzen, et al study highlights the powerful combination of detection, density, and texture analysis in identifying women at high risk of breast cancer. With Biomediq's expertise now part of ScreenPoint, we’re advancing Transpara’s capabilities to deliver even greater value for radiologists and women. Read more here: https://lnkd.in/ex9na8vw #HealthAI #HealthTech

Only a single prior? It’s not enough to make a difference for radiologists. #Transpara 2.1 includes temporal comparison across up to 6 years of prior mammograms. Why? Because subtle trends over time matter. ✅ Using multiple priors reduces false positives by up to 50% (compared to 20% with a single prior)* ✅ Gain specificity and confidence when tracking subtle changes, with fewer unnecessary callbacks Meaning? ⏫ Workflow: Detect subtle changes efficiently ⭐ Confidence: Stable lesions decrease risk score 📈 Results: Save time for the cases that need it #MovingForwardTranspara #HealthAI #BreastAI *Internal data held on file **Temporal comparison not commercially available in all regions. Please consult your local team regarding current compatibility and availability.

Estamos muy emocionados de ver que la Dra. Paulina Neira de Clínica MEDS utiliza nuestra tecnología. En un artículo reciente en la publicación El Mercurio, la Dra. Neira compartió la forma en que #Transpara ayudará a las mujeres de todo Chile a obtener mejores resultados de mamografía. Ya sea al otro lado del océano o justo en su patio trasero, los usuarios confiables confían en Transpara para marcar la diferencia para las mujeres.   ---------------------------- We are so excited to see our technology being used by Dr. Paulina Neira from Clinica MEDS. In a recent feature in the publication El Mercurio, Dr. Neira shared the way in which Transpara will help women throughout Chile receive improved mammography results. Whether it's across the ocean or right in your backyard, trusted users trust #Transpara to make a difference for women. Clínica MEDS JON PAUL C.

🔥 Now performing at the level of the top 10% of radiologists 🔥 Our latest (and annual) algorithm update delivers on its promise. ✅ Read up to 80% of the screening population without marks (low risk), with ✅ 99.97% negative predictive value (NPV) ✅ FDA cleared Read faster. Stay confident. #Transpara is here as a concurrent reading support FOR radiologists to enhance WORKFLOW, CONFIDENCE, and RESULTS. The future of breast cancer screening. #MovingForwardTranspara #HealthAI #BreastAI (Rodriguez Ruiz et al, ECR 2024) 

New year, new you, new job at a leading #AI company in the fight against breast cancer? At #Transpara, we don’t just build AI... we create an environment where you learn, grow, and get inspired. Imagine working alongside a passionate team and attending exclusive talks in our office with renowned radiologists and scientists sharing insights from cutting-edge research and clinical advancements. Explore roles like QA Test Engineer and AI Research Engineer, where you can combine technology with real-world impact. Join us at #LifeatScreenPoint🌷 https://lnkd.in/eK6a4dMH #hiring